Results 51 to 60 of about 12,002 (336)
Recent advances in smart biotechnology: Hydrogels and nanocarriers for tailored bioactive molecules depot [PDF]
, 2017 Over the past ten years, the global biopharmaceutical market has remarkably grown, with ten over the top twenty worldwide high performance medical treatment sales being biologics.Antunes, Filipe E., Coelho, Jorge F. J., Dapas, Barbara, Farra, Rossella, Fonseca, Ana C., Giordani, Silvia, Grassi, Gabriele, Grassi, Mario, Lettieri, Stefania, Marizza, Paolo, Medronho, Bruno, Milcovich, Gesmi, Perrone, Francesca +12 morecore +2 more sourcesReview of structural design guiding the development of lipid nanoparticles for nucleic acid delivery [PDF]
, 2023 Lipid nanoparticles (LNPs) are the most versatile and successful gene delivery systems, notably highlighted by their use in vaccines against COVID-19.Campbell, Richard A.,, Cárdenas, Marité,, Lawrence, M. Jayne,, Lund University., Sebastiani, Federica,, Yanez Arteta, Marianna, +5 morecore +1 more sourceSynthetic Nanoparticles for Vaccines and Immunotherapy [PDF]
, 2015 The immune system plays a critical role in our health. No other component of human physiology plays a decisive role in as diverse an array of maladies, from deadly diseases with which we are all familiar to equally terrible esoteric conditions: HIV ...Adamina M., Ahn S., Alizadeh D., Alvarez I. B., Amanna I. J., Amigorena S., Anderson R. P., Arias M. a, Ataman-Onal Y., Bachmann M. F., Bachmann M. F., Bagchi A., Bal S. M., Banchereau J., Barhate G., Barhate G., Beduneau A., Beeton C., Benson D. M., Bershteyn A., Bertholon I., Black M., Blander J. M., Blander J. M., Bonnaud C., Brandtzaeg P., Broaders K. E., Brode S., Brown J. M., Burchill M. A., Bures P., Cario E., Carrasco Y. R., Centers for Disease Control and Prevention, Cerutti A., Cha E., Chabot S., Chabot S. M., Chackerian B., Chackerian B., Champion J. A., Champion J. A., Chang L.-J., Choi J., Chou L. Y. T., Clark R. A., Couzin-Frankel J., Crespo J., Cruz L. J., Cu Y., Darrell J. Irvine, Davis M. E., Davis M. J., De Titta A., Demento S. L., Demento S. L., Demento S. L., Deretic V., Desai M. P., Di Giacomo A. M., Dijkstra J. A. N., Dintzis H. M., Dintzis R. Z., Diwan M., Dolina J. S., Dostert C., Dou H., Dou H., Dudeja P. K., Duivenvoorden R., Eisenbarth S. C., Elamanchili P., Endsley A. N., Ensign L. M., Ensign L. M., Fahmy T. M., Fang R. H., Fernandez-Urrusuno R., Fievez V., Fife B. T., Fifis T., Fifis T., Foged C., Franchi L., Fraser C. C., Freeling J. P., Friede M., Fröhlich E., Gallucci S., Gatto D., Gebril A., Gerner M. Y., Getts D. R., Gharagozloo M., Gilliet M., Glenn G. M., Grupp S. A., Gungor B., Gupta P. N., Gupta P. N., Hajdu P., Hamad I., Hamdy S., Hamdy S., Hanlon D. J., Hanniffy S. B., Hanson M. C., Harde H., Harding C. V., Harding C. V., Harris J., Hasegawa T., Hejazi R., Helling F., Himeno A., Hirosue S., Hodi F. S., Hoffmann E., Hornung V., Hu Y., Hu Y., Hunter Z., Huynh N. T., Ilyinskii P. O., Ingale S., Irvine D. J., Ishii M., Iwasaki A., Iwasaki A., Iwasaki A., Jain S., Jain S., Janeway C. A., Jewell C. M., Jin B., Joffre O. P., Jones M.-C., Junt T., Kamaly N., Kaminskas L. M., Kasturi S. P., Kavya Rakhra, Kawai T., Keller S., Kim Y.-M., Kinman L., Kitaoka M., Klavinskis L. S., Klebanoff C. A., Kolaczkowska E., Kool M., Kourtis I. C., Kovacsovics-Bankowski M., Kovacsovics-Bankowski M., Kuo-Haller P., Kuznetsov V. A., Kwong B., Kwong B., Lai S. K., Lanzavecchia A., Laroui H., Lee I. H., Leonard J. P., Leuschner F., Li A. V., Li A. V., Li H., Li N., Li P., Lico C., Liu H., Liu Z., Locke L. W., Look M., Look M., Lv H., Mabbott N. A., Macho Fernandez E., Maeda H., Maier T., Maisel K., Maldonado R. a., Mandraju R., Manolova V., Martinez F. O., Matzinger P., Matzinger P., Maus M. V., Mbow M. L., McKee A. S., McNamara J. O., Melissa C. Hanson, Mellman I., Mellman I., Minguet S., Minguet S., Mishra D., Mittal A., Modery-Pawlowski C. L., Moghimi S. M., Mohri K., Moon J. J., Moon J. J., Moon J. J., Morefield G. L., Movahedi K., Moyano D. F., Moyle P. M., Mueller S. N., Mukai Y., Muraoka D., Murray P. J., Nakamura T., Nakamura T., Napolitani G., Nehaus V., Nembrini C., Ni X., Niikura K., Niu L., Nochi T., Nordly P., Ochiel D. O., Okada E., Okazaki T., Oussoren C., Oyewumi M. O., Panelli M. C., Panzarini E., Park J., Park J., Pasare C., Perica K., Perisé-Barrios A. J., Petersen L. K., Phan T. G., Pinheiro M., Plapied L., Ralli-Jain P., Rancan F., Rappuoli R., Ravindran R., Reddy S. T., Reddy S. T., Reis e Sousa C., Restifo N. P., Riese P., Rodríguez-Limas W. a., Rosalia R. A., Rosalia R. A., Russell D. G., Sah H., Salata O., Salman H. H., Saluja S. S., Sanders M. T., Sarma J. V., Sawaengsak C., Scheerlinck J.-P. Y., Schietinger A., Seong S.-Y., Serramía M. J., Sharp F. a, Shen H., Sheridan B. S., Shi C., Shima F., Silva A. L., Slütter B., Slütter B., Smirnov D., Smith B. R., Smith B. R., Smith D. M., Sneh-Edri H., Snyder A., Soboll G., Sokolova V., Solbrig C. M., St. John A. L., Stano A., Stano A., Stano A., Stefanick J. F., Stefanick J. F., Steinman R. M., Stephan M. T., Stephan M. T., Stylianou E., Sun B., Tacken P. J., Takano S., Talar Tokatlian, Tanaka Y., Taneichi M., Tang R., Temchura V. V., Thomas S. N., Thornton E. E., Tobio M., Tomita Y., Topalian S. L., Torres A. G., Tsai S., Tsai S., Tsai S., Tsuji K., Turley D. M., Ulery B. D., Vajdy M., Van der Vlies A. J., Van Lehn R. C., Van ’t Klooster G., Vanlandschoot P., Vicente S., Villa C. H., Vinay D. S., Waeckerle-Men Y., Waeckerle-Men Y., Walter S., Wang C., Wang T., Wang Y.-Y., Wang Z., Watson D. S., Weber J., Wijagkanalan W., Williams G. R., Wilson J. T., Wira C. R., Woodrow K. a., Wright H. L., Wu T. Y., Xia Y., Xiao Y., Xing Y., Xu J., Xu L., Xu Q.-H., Yan S., Yates R. M., Yeaman G. R., Yee C., Yeh T.-H., Yeste a., Yu S. S., Yuan H., Yuba E., Yuba E., Zeltins A., Zeng R., Zhang S., Zhang Z., Zheng Y., Zhu Q., Zhu Q., Zoete M. R. De +356 morecore +1 more sourceLipid nanomaterials-based RNA therapy and cancer treatment
Acta Pharmaceutica Sinica B, 2023 We summarize the most important advances in RNA delivery and nanomedicine. We describe lipid nanoparticle-based RNA therapeutics and the impacts on the development of novel drugs. The fundamental properties of the key RNA members are described.Xingcai Zhang, Luo Hai, Yibo Gao, Guocan Yu, Yingli Sun +4 moredoaj +1 more sourceAssessing Lipid Nanoparticle Protein Corona Formation and Cytocompatibility
British Journal of Pharmacy, 2023 Lipid nanoparticles(LNPs) represent an emerging new modality for mRNA delivery. Following administration and interaction with blood constituents, LNPs form a corona complex consisting of proteins adsorbed on the surface altering their stability ...Rand Abdulrahman, Huda Ibrahem , Amna Mahmood , Kevin Edward Treacher, Robin Bruno Capomaccio, Catherine Vasey, Yvonne Perrie, Zahra Rattray +7 moredoaj +1 more sourceSite Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. [PDF]
, 2019 Nucleic Acid Therapeutics (NATs), including siRNAs and AntiSense Oligonucleotides (ASOs), have great potential to drug the undruggable genome. Targeting siRNAs and ASOs to specific cell types of interest has driven dramatic improvement in efficacy and ...Cui, Xianshu, Dowdy, Steven F, Huggins, Ian J, Jadhav, Satish, Medina, Carlos A, Springer, Aaron D, van den Berg, Arjen +6 morecore +1 more source
